CompletedNot Applicable

Residual Replication of HIV-1 in the Gut Associated Lymphoid Tissue (GALT) of Patients on Highly Active Antiretroviral Therapy (HAART): the ANRS EP 44 Study

France30 participantsStarted 2008-09

Plain-language summary

HIV-1 cannot be eradicated from infected individuals by current antiretroviral regimens. Cellular reservoirs and tissue sanctuary sites allow latent HIV-1 persistence and ongoing low-level virus replication. This project aims to characterize the residual replication of HIV-1 in subjects on antiretroviral therapy, particularly in the gut-associated lymphoid tissue.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * HIV-1 infection (ELISA and western-blot tests) * Continuous antiretroviral therapy \>= 12 months * Plasma HIV-1 RNA =\< 40 copies/ml \>= 6 months * Indication of gastro-intestinal endoscopy * Age \>= 18-year old * Physical examination * Informed consent Exclusion Criteria: * Plasma HIV-1 RNA \> 40 copies/ml in the last 6 months * Involvement in a HIV vaccine study * Treatment with interferon-alpha or PEG- interferon-alpha in the last 6 months * Treatment with interleukin-2 in the last 6 months * Decompensated cirrhosis * Abnormal hemostasis tests * Inflammatory bowel disease ; coeliac disease * Lymphoma * Blood transfusion in the last 6 months * Absence of social security (health insurance) * Pregnant or breastfeeding woman * Incapable adult

What they're measuring

Correlation between HIV-1 viral load and CD4+ T lymphopenia in the GALT.

Trial details

NCT IDNCT01038401

SponsorANRS, Emerging Infectious Diseases

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2010-05

View on ClinicalTrials.gov More HIV Infection trials